Figure 1
From: Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
Study Flow. Of the 44 patients without SVR data available, 17 patients terminated treatment earlier, 4 patients passed away and 23 patients lost to follow.
